Monopar Therapeutics (NASDAQ:MNPR) Stock: Insider Kim Tsuchimoto Sells 2,891 Shares

Monopar Therapeutics Inc. (NASDAQ:MNPR) Director Kim Tsuchimoto sold 2,891 shares of the stock in a transaction dated Wednesday, November 4th. The stock was sold at an average price of $71.26, for a total value of $206,012.66. Following the sale, the director owned 1,199 shares of the company’s stock, valued at approximately $85,440.74. The trade was a 70.68% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Monopar Therapeutics Trading Down 7.7%

Shares of Monopar Therapeutics stock opened at $67.22 on Friday. The business has a 50-day moving average price of $87.73 and a two-hundred day moving average price of $77.39. Monopar Therapeutics Inc. has a 1-year low of $50.07 and a 1-year high of $124.82.

Monopar Therapeutics (NASDAQ:MNPR) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.62) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.64) by $0.02. On average, sell-side analysts forecast that Monopar Therapeutics Inc. will post -2.98 earnings per share for the current year.

Key Headlines Impacting Monopar Therapeutics

Here are the key news stories impacting Monopar Therapeutics this week:

• Neutral Sentiment: Monopar was projected to announce quarterly earnings on Thursday. The article did not provide results or specific expectations, leaving investors to look for updates in the report. Monopar earnings announcement preview
• Neutral Sentiment: A separate article about investment firms’ views on MNPR supplied no details on ratings, price targets, or recent positioning. Investment firms’ views on MNPR
• Negative Sentiment: Directors Kim Tsuchimoto and Raymond Anderson reported share sales. Tsuchimoto sold 2,891 shares on Nov. 4 and 1,199 on Nov. 2; Anderson sold 3,142 shares on Nov. 2. The sales reduced their holdings and could weigh on sentiment, though they were executed under pre-arranged Rule 10b5-1 plans. SEC filing on director share sales

Analyst Upgrades and Downgrades

MNPR has been the subject of a number of research analyst reports. Barclays reiterated an “overweight” rating and issued a $145.00 target price (up from $128.00) on shares of Monopar Therapeutics in a report on Friday, September 11th. Weiss Ratings restated a “sell (d-)” rating on shares of Monopar Therapeutics in a report on Thursday, October 15th. UBS Group set a $125.00 price target on Monopar Therapeutics in a report on Thursday, July 23rd. Morgan Stanley reaffirmed an “overweight” rating and set a $130.00 price objective on shares of Monopar Therapeutics in a research report on Monday, August 17th. Finally, BTIG Research raised their price objective on shares of Monopar Therapeutics from $117.00 to $133.00 and gave the stock a “buy” rating in a research report on Wednesday, August 12th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Monopar Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $122.00.

Institutional Investors Weigh In On Monopar Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of MNPR. Bank of New York Mellon Corp acquired a new position in shares of Monopar Therapeutics during the second quarter valued at about $7,124,000. Bank of America Corp DE boosted its position in shares of Monopar Therapeutics by 838.2% during the 1st quarter. Bank of America Corp DE now owns 59,699 shares of the company’s stock worth $3,271,000 after purchasing an additional 53,336 shares in the last quarter. ADAR1 Capital Management LLC boosted its position in shares of Monopar Therapeutics by 13.0% during the 1st quarter. ADAR1 Capital Management LLC now owns 264,278 shares of the company’s stock worth $14,480,000 after purchasing an additional 30,370 shares in the last quarter. The Manufacturers Life Insurance Company bought a new position in shares of Monopar Therapeutics during the 1st quarter worth about $250,000. Finally, Siren L.L.C. grew its stake in shares of Monopar Therapeutics by 27.2% in the 1st quarter. Siren L.L.C. now owns 270,118 shares of the company’s stock valued at $14,800,000 after buying an additional 57,820 shares during the period. 1.83% of the stock is owned by institutional investors.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing investigational therapies for cancer. The company’s research programs are centered on radiopharmaceuticals and oncology treatments intended to improve the diagnosis and treatment of serious malignancies.

Monopar’s pipeline includes MNPR-101-Zr, a zirconium-89-labeled antibody fragment being developed as a positron emission tomography imaging agent targeting the urokinase plasminogen activator receptor, or uPAR.